Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Abbott

What to Expect From Abbott Laboratories' Next Quarterly Earnings Report

Abbott Laboratories will release its third-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Barchart

Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device.

Benzinga

3 Dividend Kings That Pay - and Beat the Market Too

These Dividend Kings are outperforming the S&P 500 in 2025 while extending decades of payout growth and earning strong buy ratings.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Quinta Brunson Said Abbott Elementary's Season 5 Christmas Episode Will Be 'A Game Changer,' And I Have A Few Wild Guesses About Why

Hear me out...

Cinemablend

Why Abbott Elementary Doesn’t Want To Go ‘The Easy Route’ With Janine And Gregory’s Relationship In Season 5

Janine and Gregory fans can celebrate!

Cinemablend

Are Wall Street Analysts Predicting Abbott Laboratories Stock Will Climb or Sink?

As Abbott Laboratories has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

‘A Goal of Ours’—U.S. Soccer Standouts Talk Growth of Game Ahead of PL Summer Series

Tyler Adams and Tim Howard spoke to Sports Illustrated about the growth of soccer in the U.S.

Sports Illustrated

Read news from The Economist, FT, and more,
with one subscription

3 Dividend Stocks With 100+ Years of History and Sky-High Growth

These three century-old companies boast strong buy ratings, 50%+ dividend growth, and rock-solid fundamentals—ideal picks for long-term income investors.

Barchart

Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield

Abbott Laboratories' dividend is safe, the pipeline is strong, and the outlook for growth is positive, making the July price dip a buying opportunity.

MarketBeat

Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors

Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but the stock still plummeted nearly 10% after management dialed back earnings and growth projections for the rest of the year.

Benzinga

Abbott Laboratories Sheds 8% On A Rare Guidance Miss

Abbott stock toppled Thursday after the health giant issued a light organic sales outlook for 2025, though it beat quarterly estimates.

Investors Business Daily

Always Sunny In Philadelphia's Gang Was Back At Their Worst In The Abbott Elementary Crossover, But Quinta Brunson Shocked Me With The Biggest Spit Take Moment

Quinta Brunson's Janine vs. Kaitlin Olson's Dee!

Cinemablend

Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids

Shares of Dexcom, Tandem Diabetes and Insulet skidded Tuesday on a proposal that would cut Medicare reimbursements for wearable diabetes tech.

Investors Business Daily

Quinta Brunson: Abbott Elementary cast would 'love to pursue other projects'

Quinta Brunson feels "blessed" that Abbott Elementary is still popular but admitted she's looking forward to a different role in the future.

BANG Premier

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

2 ‘Strong Buy’ Stocks That the MAHA Movement AND Wall Street Love

Policies associated with the MAHA movement could boost these two stocks significantly.

Barchart

What to Expect From Abbott Laboratories' Q2 2025 Earnings Report

Abbott is poised to release its second-quarter results next month, and analysts project a single-digit earnings growth.

Barchart

3 Dividend Growth Stocks To Buy and Hold Forever

These three companies have a high 5-year dividend yield, providing long-term stability while maximizing income.

Barchart

3 Dividend Aristocrats With Explosive Earnings and Bulletproof Payouts

Discover 3 Dividend Aristocrats with high earnings growth, low payout ratios, and strong analyst ratings: perfect for long-term income investors.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Abbott Laboratories Stock: Is ABT Outperforming the Health Care Sector?

Abbott Laboratories has outperformed the Health Care sector over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

The 3 Most Powerful Dividend Kings You’ve Probably Overlooked

These three Dividend Kings have strong cash flow and EPS growth, making a compelling case for long-term income investors.

Investors Business Daily

How Boston Scientific's Surprise Setback Bolstered Two Of Its Top Rivals

Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems.

Barchart

3 Oversold Dividend Aristocrats Wall Street Says Are Ready to Rally

Markets rise on improving geopolitical sentiment, leaving some quality dividend stocks to remain oversold.

Barchart

Is Wall Street Bullish or Bearish on Abbott Laboratories Stock?

As Abbott Laboratories has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Wall Street’s Best-Kept Secret? These 3 Dividend Stocks Are Outperforming Big Tech

These three Dividend Kings are beating the market in 2025, offering strong yields, reliable growth, and solid analyst buy ratings.

RideApart

MotoAmerica Revolutionises Rapid Concussion Testing in Sport With New Blood Test

The last time a helmet saved my life, I certainly wasn't feeling right for some time. I was dizzy, to say the least, but did I have a concussion? I don't know, and that's a problem in motorcycle racing. I continued to ride that day, but if I'd had Abbott's…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.